Kite Pharma Inc (KITE) Shares Bought by Legal & General Group Plc

Legal & General Group Plc grew its stake in Kite Pharma Inc (NASDAQ:KITE) by 18.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,252 shares of the biopharmaceutical company’s stock after buying an additional 3,288 shares during the period. Legal & General Group Plc’s holdings in Kite Pharma were worth $3,821,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Fred Alger Management Inc. boosted its stake in Kite Pharma by 128.6% during the 2nd quarter. Fred Alger Management Inc. now owns 16,000 shares of the biopharmaceutical company’s stock worth $1,659,000 after purchasing an additional 9,000 shares during the period. Prudential PLC acquired a new stake in Kite Pharma during the 2nd quarter worth $2,873,000. Vanguard Group Inc. boosted its stake in Kite Pharma by 9.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,998,269 shares of the biopharmaceutical company’s stock worth $414,501,000 after purchasing an additional 336,722 shares during the period. Prudential Financial Inc. boosted its stake in Kite Pharma by 26.3% during the 2nd quarter. Prudential Financial Inc. now owns 5,000 shares of the biopharmaceutical company’s stock worth $518,000 after purchasing an additional 1,040 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Kite Pharma by 71.1% during the 2nd quarter. Wells Fargo & Company MN now owns 83,230 shares of the biopharmaceutical company’s stock worth $8,628,000 after purchasing an additional 34,581 shares during the period. Institutional investors and hedge funds own 87.72% of the company’s stock.

Kite Pharma Inc (KITE) opened at $179.79 on Friday. The stock has a market cap of $10,280.00 and a PE ratio of -26.06. Kite Pharma Inc has a twelve month low of $39.82 and a twelve month high of $179.95.

In other Kite Pharma news, insider Shawn Tomasello sold 4,203 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $755,110.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Cynthia M. Butitta sold 4,228 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $759,602.48. Following the transaction, the chief operating officer now owns 125,795 shares of the company’s stock, valued at $22,600,329.70. The disclosure for this sale can be found here. Insiders sold a total of 48,936 shares of company stock valued at $8,791,842 in the last quarter. Insiders own 14.00% of the company’s stock.

Several research firms have recently commented on KITE. Wedbush upgraded shares of Kite Pharma from an “underperform” rating to a “neutral” rating in a research note on Tuesday, August 29th. Canaccord Genuity cut shares of Kite Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th. Guggenheim cut shares of Kite Pharma from a “buy” rating to a “neutral” rating and set a $128.00 target price for the company. in a research note on Monday, August 28th. SunTrust Banks cut shares of Kite Pharma from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Finally, BTIG Research cut shares of Kite Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, August 28th. Thirteen analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $94.68.

TRADEMARK VIOLATION WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/23/kite-pharma-inc-kite-shares-bought-by-legal-general-group-plc.html.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Want to see what other hedge funds are holding KITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kite Pharma Inc (NASDAQ:KITE).

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit